Company news
Zhejiang Hisun Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
November 2, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Report for Q3 2026
October 27, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Notice on Convening the 4th Extraordinary General Meeting in 2026
October 27, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Signing of Patented Technology Platform and Product Licensing Cooperation Agreement
October 27, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Resolutions of the 19th Meeting of the 10th Board of Directors
October 27, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading
October 20, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Operating Data for the First Three Quarters of 2026
October 16, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
October 13, 2026
(600267)"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval for Veterinary Drug Product Approval Number by Subsidiary
October 9, 2026
Indicative Announcement on Results of the Agreement-based Transfer of the Company's Shares by Shareholder Holding More Than 5% of the Shares through Public Solicitation and Signing of the Share Transfer Agreement with the Transferee
September 27, 2026
Announcement on Obtaining the Approval for Veterinary Drug Product Approval Number by a Subsidiary
September 14, 2026
Announcement on the Company's Product Passing the U.S. Self-GRAS Certification
September 11, 2026
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
September 10, 2026
Announcement on Obtaining New Veterinary Drug Registration Certificate by Subsidiary
September 7, 2026
Indicative Announcement on Convening the 3rd Extraordinary General Meeting in 2026
September 3, 2026
Announcement on Change of Board Secretary
August 25, 2026
Announcement on the Obtainment of CEP Certificate for Epirubicin Hydrochloride Active Pharmaceutical Ingredient
August 24, 2026
Announcement on Release of Overdue Guarantee for an Investee Subsidiary
August 20, 2026
Announcement on the Company's Proposed Selection in the National Centralized Drug Procurement
August 3, 2026
Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned Subsidiary
July 24, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
July 20, 2026
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2026
July 13, 2026
Announcement on Expected Increase in Semi-annual Performance for 2026
July 10, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
July 3, 2026
Announcement on the Signing of an Exclusive Product Licensing and Cooperation Agreement
July 3, 2026
Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary
June 30, 2026
Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Letermovir API
June 29, 2026
Announcement on Implementation of the 2nd Share Repurchase Cancellation and Share Capital Changes
June 17, 2026
Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Finerenone API
June 11, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 8, 2026
Announcement on Obtaining Drug Registration Certificate
May 21, 2026
Announcement on Outline of Reception Day for Investors
April 29, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 28, 2026
Report for Q1 2026
April 27, 2026
Indicative Announcement on Convening the 2025 Annual General Meeting
April 20, 2026
Announcement on Preliminary Earnings Estimate for Q1 2026
April 15, 2026
Announcement on Estimated Daily Related Party Transactions in 2026
April 7, 2026
Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
April 1, 2026
Announcement on Convening the 2025 Annual Performance Briefing
March 30, 2026
Announcement on the Company's Drug Passing Consistency Evaluation of Generic Drug
March 26, 2026
Announcement on Implementation Results of the 4th Share Repurchase and Share Changes
March 17, 2026
Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
March 16, 2026
Correction Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right
March 10, 2026
Announcement on Proposed Transfer of Shares by Shareholders Holding over 5% Shares by Agreement through Public Solicitation and Change of Control Right
March 3, 2026
Announcement on the Veterinary Drug Product Approval Number Obtained by a Subsidiary
March 2, 2026
Announcement on the Obtainment of CEP Certificate for Ticagrelor Active Pharmaceutical Ingredient
February 24, 2026
Announcement on Lifting Trading Restrictions in the 3rd Trade Restriction Release Period for Reserved Granted Parts under 2021 Restricted Stock Incentive Plan and Stock Marketing
February 10, 2026
Announcement on Progress in Capital Increase and Debt-to-Share Swap Matters of Zhejiang Dtrm BioPharma Co., Ltd.
February 5, 2026
Announcement on Progress in Repurchasing Shares through Call Auction for the 4th Time
February 2, 2026
Announcement on Approval by the US FDA of the Formulation Product Micafungin Sodium for Injection of the Wholly-owned Subsidiary
January 23, 2026